Peter Lichtlen, MD, PhD

Chief Medical Advisor

 

Dr. Lichtlen is the Chief Medical Advisor at EffRx. Prior to EffRx, he served as Chief Medical Officer (CMO) at Sucampo Pharmaceuticals, Inc (Nasdaq: SCMP) until its $1.2B acquisition by Mallinckrodt in early 2018.

He is also a founder, Board Member, and acting CMO at Numab AG in Switzerland. Prior to co-founding Numab AG in 2011, Dr. Lichtlen was the Head of Clinical R&D at ESBATech AG (acquired by Alcon/Novartis in 2009) until end of 2010. Besides his CMO role at Numab AG and his consultancy role at EffRx, Dr. Lichtlen also is a member of the Board of Directors at Lysogene SA (EN Paris: LYS), a clinical-stage gene therapy company active in the area of rare neurodegenerative diseases.

He is the author of more than 20 peer-reviewed scientific and clinical articles and holds several issued patents. Dr. Lichtlen received his MD and PhD in Molecular Biology both from the University of Zurich, Switzerland.